GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

In fact, more and more teens that meet certain weight and health criteria are going on GLP-1s after the FDA’s approval of ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...

Hims stock jumped late Monday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.

A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Compared with placebo, once-weekly semaglutide significantly reduced body weight, knee osteoarthritis-related pain, and improved physical function. Topline results were announced from a phase 3 ...

The update comes as the FDA revised its shortage list to note that the .25 mg starter dose of semaglutide-based obesity med Wegovy is now available in the U.S. In October, Novo Nordisk shared data ...